MAMelika Abrishami

Melika Abrishami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Melika Abrishami has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mechanistic Insights into the Differential Efficacy of Sonratoclax against Venetoclax-Resistant BCL2 G101V

    by Yashmin Afshar, Ali Goli, Melika Abrishami

    Resistant mechanisms to venetoclax, a selective BCL-2 inhibitor approved for hematological malignancies, are frequently mediated by the G101V mutation in BCL-2. Sonrotoclax illustrates superior potency against both wild-type and G101V-mutated BCL-2, yet the mechanistic basis remains unclear. This study employed computational methods to investigate the binding dynamics of both inhibitors. Structures were predicted with AlphaFold, refined via molecular dynamics simulations (MDS), and ligands were docked with AutoDock Vina. Four systems were subjected to triplicate 200 ns MDS, with analyses including RMSD, RMSF, buried surface area, protein-ligand interaction fingerprint, and MM/GBSA binding free energies. Results indicate venetoclax exhibits progressive dissociation from G101V BCL-2, with elevated RMSD, reduced buried surface area, and increased unbound states. In contrast, Sonrotoclax maintains a steady correlation, shows persistence with entropy-enthalpy compensation, displays negligible unbound time, higher binding free energies, and constant van der Waals anchors. Having all these results in mind, a "Dynamic Blockade" hypothesis is proposed, where Sonrotoclax's flexibility enables sustained BH3 groove occupancy, blocking pro-apoptotic BH3-only proteins and overcoming allosteric perturbations induced by G101V. This mechanistic perspective proposes the optimal approach for designing resilient inhibitors to accelerate drug repurposing and development in oncology.

  • The role of gut microbiota in breast cancer: biomarker identification and therapeutic applications

    by Melika Abrishami, Mohadeseh Sabouri, Fereshte Joneidi, Zahra Haghshenas, Ghazaleh Khalili-Tanha, Elham Nazari

    Recent studies have established the gut microbiome as a crucial player in breast cancer diagnosis, progression, and treatment. Distinct microbial patterns have shown promise as non-invasive diagnostic and prognostic biomarkers, supporting patient stratification and risk assessment based on microbiota composition. The gut microbiome also modulates estrogen metabolism, influencing the risk of hormone receptor-positive breast cancer, while dysbiosis can promote chronic inflammation and tumor expansion. Moreover, accumulating evidence demonstrates that gut bacteria can alter responses to chemotherapy and immunotherapy, suggesting that microbiota modulation may enhance treatment efficacy. With the advent of omics technologies and machine learning, intricate host–microbe interactions are being decoded, revealing new molecular targets and therapeutic opportunities. Importantly, early clinical and interventional studies using probiotics, prebiotics, and fecal microbiota transplantation (FMT) are being explored to restore microbial balance, mitigate therapy-related side effects, and improve antitumor immunity in breast cancer patients. Together, these advances underscore the translational potential of microbiome research, paving the way for microbiota-guided diagnostic, prognostic, and therapeutic strategies in personalized breast cancer management.